Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

BACKGROUND: In this prospective phase 2 trial, we assessed the efficacy of trastuzumab-emtansine (T-DM1) in HER2-negative metastatic breast cancer (MBC) patients with HER2-positive CTC. METHODS: Main inclusion criteria for screening were as follows: women with HER2-negative MBC treated with ≥ 2 prio...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Breast Cancer Res
Asıl Yazarlar: Jacot, William, Cottu, Paul, Berger, Frederique, Dubot, Coraline, Venat-Bouvet, Laurence, Lortholary, Alain, Bourgeois, Hugues, Bollet, Marc, Servent, Veronique, Luporsi, Elisabeth, Espié, Marc, Guiu, Severine, D’Hondt, Veronique, Dieras, Veronique, Sablin, Marie-Paule, Brain, Etienne, Neffati, Souhir, Pierga, Jean-Yves, Bidard, Francois-Clement
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2019
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6854749/
https://ncbi.nlm.nih.gov/pubmed/31727113
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-019-1215-z
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller